88. Chronic thromboembolic pulmonary hypertension Disease details / Clinical trials / Drug dev / DR info


Clinical trials : 157 Drugs : 107 - (DrugBank : 22) / Drug target genes : 14 - Drug target pathways : 54

Drugs and their primary sponsors and trial info
ACT-064992   
   Actelion Pharmaceuticals Ltd
      2021   Phase 3   EUCTR2017-003934-10-PL   Belarus;Belgium;France;Germany;Poland;Russian Federation;Turkey;Ukraine;
   Actelion Pharmaceuticals Ltd.
      2015   Phase 2   EUCTR2013-003457-25-LT   Austria;Belgium;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;
      2015   Phase 2   EUCTR2013-002950-56-LT   Austria;Belgium;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;Vietnam;
      2015   -   EUCTR2013-003457-25-NL   Austria;Belgium;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-003457-25-HU   Austria;Belgium;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-003457-25-GB   Austria;Belgium;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Hungary;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-003457-25-FR   Austria;Belgium;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Hungary;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-003457-25-DE   Austria;Belgium;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Hungary;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-003457-25-CZ   Austria;Belgium;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-003457-25-BE   Austria;Belgium;Bulgaria;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-003457-25-AT   Austria;Belgium;Bulgaria;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-002950-56-NL   Austria;Belgium;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;Vietnam;
      2014   Phase 2   EUCTR2013-002950-56-HU   Austria;Belgium;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;Vietnam;
      2014   Phase 2   EUCTR2013-002950-56-GB   Austria;Belgium;Bulgaria;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Sweden;Switzerland;Thailand;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-002950-56-DE   Austria;Belgium;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;Vietnam;
      2014   Phase 2   EUCTR2013-002950-56-CZ   Austria;Belgium;Bulgaria;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Sweden;Switzerland;Thailand;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-002950-56-BE   Austria;Belgium;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;Vietnam;
      2014   Phase 2   EUCTR2013-002950-56-AT   Austria;Belgium;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;Vietnam;
ACT-293987   
   ACTELION PHARMACEUTICALS LTD
      2019   Phase 3   EUCTR2018-002823-41-IT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
   Actelion Pharmaceuticals Ltd
      2019   Phase 3   EUCTR2018-002823-41-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002823-41-NL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002823-41-HU   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;Finland;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002823-41-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002823-41-DK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002823-41-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002823-41-CZ   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Finland;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002823-41-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002823-41-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002823-41-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;Finland;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Adempas   
   Bayer AG
      2009   Phase 3   EUCTR2008-003539-19-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
   Bayer AG
      2013   Phase 3   EUCTR2012-002104-40-PT   Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-003539-19-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
   Bayer HealthCare AG
      2013   Phase 3   EUCTR2012-002104-40-GB   Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002104-40-CZ   Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-002104-40-NL   Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   Phase 3   EUCTR2008-003539-19-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-003539-19-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-003539-19-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-003539-19-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
Adempas (Riociguat, BAY63-2521)   
   Bayer
      2013   -   NCT01784562   Austria;Belgium;Canada;Colombia;Czech Republic;Denmark;France;Germany;Italy;Japan;Mexico;Netherlands;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
Adempas (active agent riociguat)   
   Thoraxklinik Heidelberg gGmbH
      2021   Phase 4   EUCTR2020-005462-34-DE   Germany;
Adempas®   
   International CTEPH Association (ICA)
      2018   Phase 2   EUCTR2017-001121-40-GB   France;Germany;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-001121-40-FR   France;Germany;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-001121-40-DE   France;Germany;United Kingdom;United States;
Ambrisentan   
   GlaxoSmithKline
      2014   Phase 3   NCT01894022   Argentina;Austria;Canada;China;Czech Republic;Czechia;Germany;Israel;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Saudi Arabia;Spain;United Kingdom;United States;
      2013   Phase 3   NCT01884675   Argentina;Austria;Canada;China;Czech Republic;Germany;Israel;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Saudi Arabia;Spain;United Kingdom;United States;
   GlaxoSmithKline Research & Developement Ltd
      2014   Phase 3   EUCTR2012-001646-18-IT   Argentina;Austria;Brazil;Canada;China;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United Kingdom;
      2013   -   EUCTR2012-001646-18-NL   Argentina;Austria;Brazil;Canada;China;Czech Republic;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;
      2013   -   EUCTR2012-001646-18-GB   Argentina;Austria;Brazil;Canada;China;Czech Republic;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;
      2013   -   EUCTR2012-001646-18-DE   Argentina;Austria;Brazil;Canada;China;Czech Republic;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;
      2013   -   EUCTR2012-001646-18-CZ   Argentina;Austria;Brazil;Canada;China;Czech Republic;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;
      2013   -   EUCTR2012-001646-18-AT   Argentina;Austria;Brazil;Canada;China;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United Kingdom;
   GlaxoSmithKline, S.A.
      2013   -   EUCTR2012-001646-18-ES   Argentina;Austria;Brazil;Canada;China;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
Ammonia   
   Ottawa Heart Institute Research Corporation
      2014   Phase 2   NCT02094001   Canada;
Atorvastatin   
   Tongji Hospital of Tongji University
      2008   -   ChiCTR-TNRC-08000263   China;
BAY 63-2521   
   Bayer HealthCare AG
      2008   Phase 3   EUCTR2007-000072-16-IT   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2006   Phase 1;Phase 2   EUCTR2006-003520-10-DE   Germany;
   International CTEPH Association (ICA)
      2018   Phase 2   EUCTR2017-001121-40-GB   France;Germany;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-001121-40-FR   France;Germany;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-001121-40-DE   France;Germany;United Kingdom;United States;
BAY 63-2521 IR coated tablet   
   Bayer HealthCare AG
      2013   Phase 3   EUCTR2012-002104-40-GB   Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
BAY 63-2521 IR tablet   
   Bayer AG
      2013   Phase 3   EUCTR2012-002104-40-PT   Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002104-40-DE   Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Bayer HealthCare AG
      2013   Phase 3   EUCTR2012-002104-40-SE   Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002104-40-CZ   Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-002104-40-BE   Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-002104-40-NL   Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-002104-40-IT   Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-002104-40-ES   Austria;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-002104-40-DK   Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-002104-40-AT   Austria;Belgium;Brazil;Canada;Colombia;Czech Republic;Denmark;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Portugal;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
BAY 63-2521 coated tablets   
   Bayer AG
      2009   Phase 3   EUCTR2008-003539-19-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
   Bayer AG
      2009   Phase 3   EUCTR2008-003539-19-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
   Bayer HealthCare AG
      2010   Phase 3   EUCTR2008-003539-19-DK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-003539-19-CZ   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-003539-19-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2009   Phase 3   EUCTR2008-003539-19-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
BAY 63-2521 tablets   
   Bayer AG
      2010   Phase 3   EUCTR2008-003539-19-SK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
   Bayer HealthCare AG
      2010   -   EUCTR2007-000072-16-DK   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2007-000072-16-SK   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2007-000072-16-BE   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2007-000072-16-AT   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   -   EUCTR2007-000072-16-PT   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   -   EUCTR2007-000072-16-NL   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   -   EUCTR2007-000072-16-IE   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   -   EUCTR2007-000072-16-CZ   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2008   Phase 3   EUCTR2008-003539-19-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2008   Phase 3   EUCTR2007-000072-16-FR   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-000072-16-ES   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      -   -   EUCTR2007-000072-16-DE   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
   Bayer HealthCare AG, Bayer Vital GmbH, D-51368 Leverkusen
      2009   Phase 3   EUCTR2008-003539-19-NL   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-003539-19-FR   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   -   EUCTR2008-003539-19-IE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
   Bayer HealthCare AG, D-51368 Leverkusen
      2009   Phase 3   EUCTR2007-000072-16-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
BAY1237592   
   Bayer
      2019   Phase 1   NCT03754660   Austria;Czechia;Germany;Poland;
BPA   
   Fukuda Keiichi
      2016   -   JPRN-jRCTs031180239   Japan;
   Fuwai Hospital, Chinese Academy of Medical Sciences
      2021   Phase 0   ChiCTR2100052570   China;
   Keio University School of Medicine
      2016   -   JPRN-UMIN000019549   Japan;
   Shanghai Pulmonary Hospital
      2021   Phase 0   ChiCTR2000032403   China;
   Shimokawahara Hiroto
      2021   Phase 2   JPRN-jRCTs041200052   Japan;
   Tatsuguchi Mariko
      2021   -   JPRN-jRCT1041200111   Japan;
   The First Affiliated Hospital of Guangzhou Medical University
      2019   -   ChiCTR2000034995   China;
Ballon Pulmonary Angioplasty   
   Medical University of Vienna
      2017   -   NCT03074539   Austria;
Balloon Pulmonary Angioplasty (BPA)   
   Assistance Publique - Hôpitaux de Paris
      2016   -   NCT02634203   France;
Bosentan   
   ACTELION PHARMACEUTICALS ITALIA
      2006   -   EUCTR2005-002900-40-IT   Czech Republic;Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-001965-33-IT   Germany;Italy;Spain;United Kingdom;
   Actelion
      2006   Phase 3   NCT00319111   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
      2005   Phase 3   NCT00313222   Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
Bosentan monohydrate   
   Actelion Pharmaceuticals Ltd.
      2006   Phase 3   EUCTR2005-002900-40-GB   Austria;Belgium;Czech Republic;Germany;Italy;Spain;United Kingdom;
      2006   -   EUCTR2005-002900-40-CZ   Czech Republic;Germany;Italy;Spain;United Kingdom;
      2006   -   EUCTR2005-002900-40-BE   Austria;Belgium;Czech Republic;Germany;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-001965-33-GB   Austria;Czech Republic;Germany;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-001965-33-CZ   Austria;Czech Republic;Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-002900-40-AT   Austria;Czech Republic;Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-001965-33-DE   Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-001965-33-AT   Austria;Germany;Italy;Spain;United Kingdom;
Catheter directed therapy   
   University of Arizona
      2021   -   NCT05133713   United States;
Edoxaban   
   Abe Kohtaro
      2021   Phase 3   JPRN-jRCT2071200098   Japan;
   Division of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine
      2016   Phase 4   JPRN-UMIN000018520   Japan;
   Kyushu University
      2021   Phase 3   NCT04730037   Japan;
GSK1325760   
   GlaxoSmithKline Research & Developement Ltd
      2014   Phase 3   EUCTR2012-001646-18-IT   Argentina;Austria;Brazil;Canada;China;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United Kingdom;
      2013   -   EUCTR2012-001646-18-NL   Argentina;Austria;Brazil;Canada;China;Czech Republic;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;
      2013   -   EUCTR2012-001646-18-GB   Argentina;Austria;Brazil;Canada;China;Czech Republic;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;
      2013   -   EUCTR2012-001646-18-DE   Argentina;Austria;Brazil;Canada;China;Czech Republic;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;
      2013   -   EUCTR2012-001646-18-CZ   Argentina;Austria;Brazil;Canada;China;Czech Republic;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;
      2013   -   EUCTR2012-001646-18-AT   Argentina;Austria;Brazil;Canada;China;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United Kingdom;
   GlaxoSmithKline Research & Developement Ltd
      2014   Phase 3   EUCTR2012-001642-17-IT   Argentina;Austria;Brazil;Canada;China;Czech Republic;Germany;Israel;Italy;Japan;Korea, Democratic People's Republic of;Mexico;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-001642-17-GB   Argentina;Austria;Brazil;Canada;China;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United Kingdom;
      2013   Phase 3   EUCTR2012-001642-17-CZ   Argentina;Austria;Brazil;Canada;China;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United Kingdom;
      2013   -   EUCTR2012-001642-17-NL   Argentina;Austria;Brazil;Canada;China;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United Kingdom;
      2013   -   EUCTR2012-001642-17-DE   Argentina;Austria;Brazil;Canada;China;Czech Republic;Germany;Italy;Japan;Mexico;Netherlands;Russian Federation;Saudi Arabia;Spain;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-001642-17-AT   Argentina;Austria;Brazil;Canada;China;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United Kingdom;
   GlaxoSmithKline, S.A.
      2013   -   EUCTR2012-001646-18-ES   Argentina;Austria;Brazil;Canada;China;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-001642-17-ES   Argentina;Austria;Brazil;Canada;China;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
Imatinib mesilate   
   Imperial College London
      2020   Phase 2   EUCTR2020-001157-48-GB   United Kingdom;
Iodine   
   University of Sheffield
      2019   -   NCT03806907   -
JNJ-67896062 / ACT-064992   
   ACTELION PHARMACEUTICALS LTD
      2020   Phase 3   EUCTR2019-004131-24-IT   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   ACTELION Pharmaceuticals Ltd.
      2020   Phase 3   EUCTR2019-004131-24-PL   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004131-24-LT   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004131-24-HU   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Czech Republic;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004131-24-GB   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004131-24-ES   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Czech Republic;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004131-24-DE   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
JNJ-67896062/ ACT-064992   
   ACTELION PHARMACEUTICALS LTD
      2020   Phase 3   EUCTR2019-004131-24-IT   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Long term oxygen therapy   
   University of Zurich
      2013   Phase 3   NCT01884012   Switzerland;
MACITENTAN COMPRESSE   
   ACTELION PHARMACEUTICALS LTD
      2020   Phase 3   EUCTR2019-004131-24-IT   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Macitentan   
   Actelion
      2020   Phase 3   NCT04271475   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   NCT03809650   Japan;
      2018   Phase 3   NCT03422328   Belarus;Belgium;France;Poland;Russian Federation;Ukraine;
      2015   Phase 2   NCT02060721   Austria;Belgium;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;Vietnam;
      2014   Phase 2   NCT02021292   Austria;Belgium;Bulgaria;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Turkey;Ukraine;United Kingdom;United States;Vietnam;
   Assistance Publique - Hôpitaux de Paris
      2021   Phase 2/Phase 3   NCT04780932   France;
   Nakano Masayoshi
      2021   Phase 3   JPRN-jRCT2051200150   Germany;Hungary;Japan;South Korea;USA;
Macitentan tablets   
   ACTELION Pharmaceuticals Ltd.
      2020   Phase 3   EUCTR2019-004131-24-PL   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004131-24-LT   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004131-24-HU   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Czech Republic;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004131-24-GB   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004131-24-ES   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Czech Republic;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004131-24-DE   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carb   
   Bayer AG
      2010   Phase 3   EUCTR2008-003539-19-SK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
   Bayer HealthCare AG
      2010   -   EUCTR2007-000072-16-DK   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2007-000072-16-SK   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2007-000072-16-BE   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2007-000072-16-AT   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   -   EUCTR2007-000072-16-PT   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   -   EUCTR2007-000072-16-NL   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   -   EUCTR2007-000072-16-IE   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   -   EUCTR2007-000072-16-CZ   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2008   Phase 3   EUCTR2008-003539-19-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2008   Phase 3   EUCTR2007-000072-16-FR   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-000072-16-ES   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      -   -   EUCTR2007-000072-16-DE   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
   Bayer HealthCare AG, Bayer Vital GmbH, D-51368 Leverkusen
      2009   Phase 3   EUCTR2008-003539-19-NL   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-003539-19-FR   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   -   EUCTR2008-003539-19-IE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
   Bayer HealthCare AG, D-51368 Leverkusen
      2009   Phase 3   EUCTR2007-000072-16-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
Methyl [4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]meth   
   Bayer HealthCare AG
      2006   Phase 1;Phase 2   EUCTR2006-003520-10-DE   Germany;
MultiHance   
   Brigham and Women's Hospital
      2013   Phase 2   NCT01953965   United States;
N-acetyl cysteine   
   Instituto Nacional de Cardiologia Ignacio Chavez
      2019   -   NCT04081012   Mexico;
NS-304   
   NIPPON SHINYAKU CO., LTD.
      2013   Phase 2   JPRN-JapicCTI-132159   -
   NIPPON SHINYAKU CO., LTD. / Actelion Pharmaceuticals Japan Ltd.
      2010   Phase 2   JPRN-JapicCTI-111667   -
      2010   Phase 2   JPRN-JapicCTI-111666   -
NS-304 Placebo   
   Nippon Shinyaku Co., Ltd.
      2016   Phase 3   JPRN-JapicCTI-163279   Japan;
Opsumit   
   Actelion Pharmaceuticals Ltd
      2021   Phase 3   EUCTR2017-003934-10-PL   Belarus;Belgium;France;Germany;Poland;Russian Federation;Turkey;Ukraine;
   Actelion Pharmaceuticals Ltd.
      2015   Phase 2   EUCTR2013-003457-25-LT   Austria;Belgium;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;
      2015   Phase 2   EUCTR2013-002950-56-LT   Austria;Belgium;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;Vietnam;
      2015   -   EUCTR2013-003457-25-NL   Austria;Belgium;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-003457-25-HU   Austria;Belgium;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-003457-25-GB   Austria;Belgium;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Hungary;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-003457-25-DE   Austria;Belgium;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Hungary;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-003457-25-BE   Austria;Belgium;Bulgaria;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-003457-25-AT   Austria;Belgium;Bulgaria;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-002950-56-DE   Austria;Belgium;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;Vietnam;
      2014   Phase 2   EUCTR2013-002950-56-CZ   Austria;Belgium;Bulgaria;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Sweden;Switzerland;Thailand;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-002950-56-BE   Austria;Belgium;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;Vietnam;
      2014   Phase 2   EUCTR2013-002950-56-AT   Austria;Belgium;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;Vietnam;
Opsumit®   
   ACTELION PHARMACEUTICALS LTD
      2020   Phase 3   EUCTR2019-004131-24-IT   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   ACTELION Pharmaceuticals Ltd.
      2020   Phase 3   EUCTR2019-004131-24-PL   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004131-24-LT   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004131-24-HU   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Czech Republic;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004131-24-GB   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Czech Republic;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004131-24-ES   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Czech Republic;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Arab Emirates;United Kingdom;United States;
      2020   Phase 3   EUCTR2019-004131-24-DE   Argentina;Australia;Austria;Bulgaria;Canada;China;Colombia;Czechia;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Poland;Romania;Russian Federation;Saudi Arabia;Serbia;Singapore;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Actelion Pharmaceuticals Ltd.
      2014   Phase 2   EUCTR2013-003457-25-FR   Austria;Belgium;Canada;Chile;China;Czech Republic;Czechia;France;Germany;Hungary;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-003457-25-CZ   Austria;Belgium;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;
      2014   Phase 2   EUCTR2013-002950-56-NL   Austria;Belgium;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;Vietnam;
      2014   Phase 2   EUCTR2013-002950-56-HU   Austria;Belgium;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Korea, Republic of;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Switzerland;Thailand;Ukraine;United Kingdom;United States;Vietnam;
      2014   Phase 2   EUCTR2013-002950-56-GB   Austria;Belgium;Bulgaria;Canada;Chile;China;Czech Republic;France;Germany;Hungary;Italy;Lithuania;Mexico;Netherlands;Poland;Russian Federation;South Africa;Sweden;Switzerland;Thailand;Ukraine;United Kingdom;United States;
Oxygen   
   Department of Cardiology, Hospital Organization Okayama Medical Center
      2015   -   JPRN-UMIN000026882   Japan;
   Heidelberg University
      2019   Phase 2   NCT04207593   Germany;
   University of Zurich
      2015   -   NCT02558582   Switzerland;
Oxygen, liquid   
   Thoraxklinik-Heidelberg gGmbH
      2019   Phase 2   EUCTR2018-001387-39-DE   Germany;
Placebo   
   NIPPON SHINYAKU CO., LTD. / Actelion Pharmaceuticals Japan Ltd.
      2010   Phase 2   JPRN-JapicCTI-111667   -
Pulmonary Endarteriectomy   
   Medical University of Vienna
      2017   -   NCT03074539   Austria;
Pulmonary endarterectomy   
   International CTEPH Association
      2018   Phase 2   NCT03273257   France;Germany;United Kingdom;United States;
Remodulin (R)   
   MRN-Medical Research Network GmbH
      2009   Phase 3   EUCTR2008-006441-10-SK   Austria;Czech Republic;Germany;Slovakia;
Remodulin 10mg/ml 20ml   
   MRN-Medical Research Network GmbH
      2010   -   EUCTR2008-006441-10-DE   Austria;Czech Republic;Germany;
Remodulin 1mg/ml 20ml   
   MRN-Medical Research Network GmbH
      2010   -   EUCTR2008-006441-10-DE   Austria;Czech Republic;Germany;
Remodulin 2.5mg/ml 20ml   
   MRN-Medical Research Network GmbH
      2010   -   EUCTR2008-006441-10-DE   Austria;Czech Republic;Germany;
Remodulin 5mg/ml 20ml   
   MRN-Medical Research Network GmbH
      2010   -   EUCTR2008-006441-10-DE   Austria;Czech Republic;Germany;
Riociguat   
   Adachi Shiro
      2021   -   JPRN-jRCT1041210122   Japan;
   Assistance Publique - Hôpitaux de Paris
      2016   -   NCT02634203   France;
   Bayer AG
      2009   Phase 3   EUCTR2008-003539-19-PT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
   Bayer AG
      2010   Phase 3   EUCTR2008-003539-19-SK   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
   Bayer HealthCare AG
      2010   -   EUCTR2007-000072-16-DK   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-003539-19-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2009   Phase 3   EUCTR2007-000072-16-SK   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2007-000072-16-BE   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2007-000072-16-AT   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   -   EUCTR2007-000072-16-PT   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   -   EUCTR2007-000072-16-NL   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   -   EUCTR2007-000072-16-IE   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   -   EUCTR2007-000072-16-CZ   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2008   Phase 3   EUCTR2008-003539-19-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2008   Phase 3   EUCTR2007-000072-16-IT   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-000072-16-FR   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2008   Phase 3   EUCTR2007-000072-16-ES   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2006   Phase 1;Phase 2   EUCTR2006-003520-10-DE   Germany;
      -   -   EUCTR2007-000072-16-DE   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
   Bayer HealthCare AG, Bayer Vital GmbH, D-51368 Leverkusen
      2009   Phase 3   EUCTR2008-003539-19-NL   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   Phase 3   EUCTR2008-003539-19-FR   Austria;Belgium;Czech Republic;Denmark;France;Germany;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;
      2009   -   EUCTR2008-003539-19-IE   Austria;Belgium;Czech Republic;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;
   Bayer HealthCare AG, D-51368 Leverkusen
      2009   Phase 3   EUCTR2007-000072-16-GB   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
   Fukuda Keiichi
      2016   -   JPRN-jRCTs031180239   Japan;
   Heidelberg University
      2021   Phase 4   NCT04954742   Germany;
   International CTEPH Association
      2018   Phase 2   NCT03273257   France;Germany;United Kingdom;United States;
   Keio University School of Medicine
      2016   -   JPRN-UMIN000019549   Japan;
   Medical University of Vienna
      2017   -   NCT03074539   Austria;
   Shanghai Pulmonary Hospital
      2021   Phase 0   ChiCTR2000032403   China;
   Shimokawahara Hiroto
      2021   Phase 2   JPRN-jRCTs041200052   Japan;
Riociguat (ADEMPAS, BAY63-2521)   
   Bayer
      2014   -   NCT02117791   Japan;
Riociguat (Adempas, BAY63-2521)   
   Bayer
      2015   -   NCT02545465   Belgium;Canada;Colombia;Denmark;Germany;Japan;Sweden;Turkey;United Kingdom;
      2009   Phase 3   NCT00910429   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Czechia;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
      2009   Phase 3   NCT00855465   Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Czech Republic;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;Spain;Switzerland;Taiwan;Turkey;United Kingdom;United States;
Riociguat Oral Tablet   
   National Hospital Organization Okayama Medical Center
      2020   Phase 2   NCT04600492   Japan;
Ro 47-0203   
   Actelion Pharmaceuticals Ltd.
      2006   Phase 3   EUCTR2005-002900-40-GB   Austria;Belgium;Czech Republic;Germany;Italy;Spain;United Kingdom;
      2006   -   EUCTR2005-002900-40-DE   Czech Republic;Germany;Italy;Spain;United Kingdom;
      2006   -   EUCTR2005-002900-40-CZ   Czech Republic;Germany;Italy;Spain;United Kingdom;
      2006   -   EUCTR2005-002900-40-BE   Austria;Belgium;Czech Republic;Germany;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-001965-33-GB   Austria;Czech Republic;Germany;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-001965-33-CZ   Austria;Czech Republic;Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-002900-40-AT   Austria;Czech Republic;Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-001965-33-DE   Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-001965-33-AT   Austria;Germany;Italy;Spain;United Kingdom;
Sauerstoff   
   Thoraxklinik-Heidelberg gGmbH
      2019   Phase 2   EUCTR2018-001387-39-DE   Germany;
Selexipag   
   Actelion
      2019   Phase 3   NCT03689244   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czechia;Denmark;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
   Adachi Shiro
      2021   -   JPRN-jRCT1041210122   Japan;
   NIPPON SHINYAKU CO., LTD.
      2013   Phase 2   JPRN-JapicCTI-132159   -
   NIPPON SHINYAKU CO., LTD. / Actelion Pharmaceuticals Japan Ltd.
      2010   Phase 2   JPRN-JapicCTI-111667   -
      2010   Phase 2   JPRN-JapicCTI-111666   -
   Nippon Shinyaku Co., Ltd.
      2016   Phase 3   JPRN-JapicCTI-163279   Japan;
Supplemental oxygen via a mask   
   University of Zurich
      2012   Phase 2   NCT01748474   Switzerland;
Systemic anticoagulation   
   University of Arizona
      2021   -   NCT05133713   United States;
TRACLEER 125MG 56CPR RIV.   
   ACTELION PHARMACEUTICALS ITALIA
      2005   -   EUCTR2005-001965-33-IT   Germany;Italy;Spain;United Kingdom;
TRACLEER*56CPR RIV   
   ACTELION PHARMACEUTICALS ITALIA
      2006   -   EUCTR2005-002900-40-IT   Czech Republic;Germany;Italy;Spain;United Kingdom;
TREPROSTINIL SODIUM   
   MRN-Medical Research Network GmbH
      2010   -   EUCTR2008-006441-10-DE   Austria;Czech Republic;Germany;
Thrombin   
   National and Kapodistrian University of Athens
      2015   -   NCT03195543   Greece;
Tracleer   
   Actelion Pharmaceuticals Ltd.
      2006   Phase 3   EUCTR2005-002900-40-GB   Austria;Belgium;Czech Republic;Germany;Italy;Spain;United Kingdom;
      2006   -   EUCTR2005-002900-40-CZ   Czech Republic;Germany;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-001965-33-GB   Austria;Czech Republic;Germany;Italy;Spain;United Kingdom;
      2005   Phase 3   EUCTR2005-001965-33-CZ   Austria;Czech Republic;Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-002900-40-AT   Austria;Czech Republic;Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-001965-33-DE   Germany;Italy;Spain;United Kingdom;
      2005   -   EUCTR2005-001965-33-AT   Austria;Germany;Italy;Spain;United Kingdom;
Treprostinil sodium   
   SciPharm SàRL
      2009   Phase 3   NCT01416636   Austria;Czech Republic;Czechia;Germany;Poland;
Uptravi   
   ACTELION PHARMACEUTICALS LTD
      2019   Phase 3   EUCTR2018-002823-41-IT   Argentina;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
   Actelion Pharmaceuticals Ltd
      2019   Phase 3   EUCTR2018-002823-41-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002823-41-NL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002823-41-HU   Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;Finland;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002823-41-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002823-41-DK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002823-41-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002823-41-CZ   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Finland;Germany;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002823-41-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Estonia;Finland;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002823-41-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;Denmark;Finland;Germany;Hungary;India;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Poland;Portugal;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-002823-41-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Denmark;Estonia;Finland;Germany;Greece;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Russian Federation;Singapore;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Volibris   
   GlaxoSmithKline Research & Developement Ltd
      2014   Phase 3   EUCTR2012-001646-18-IT   Argentina;Austria;Brazil;Canada;China;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United Kingdom;
      2013   -   EUCTR2012-001646-18-NL   Argentina;Austria;Brazil;Canada;China;Czech Republic;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;
      2013   -   EUCTR2012-001646-18-GB   Argentina;Austria;Brazil;Canada;China;Czech Republic;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;
      2013   -   EUCTR2012-001646-18-DE   Argentina;Austria;Brazil;Canada;China;Czech Republic;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;
      2013   -   EUCTR2012-001646-18-CZ   Argentina;Austria;Brazil;Canada;China;Czech Republic;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;
      2013   -   EUCTR2012-001646-18-AT   Argentina;Austria;Brazil;Canada;China;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United Kingdom;
   GlaxoSmithKline Research & Developement Ltd
      2014   Phase 3   EUCTR2012-001642-17-IT   Argentina;Austria;Brazil;Canada;China;Czech Republic;Germany;Israel;Italy;Japan;Korea, Democratic People's Republic of;Mexico;Netherlands;Russian Federation;Spain;Turkey;United Kingdom;United States;
      2013   Phase 3   EUCTR2012-001642-17-GB   Argentina;Austria;Brazil;Canada;China;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United Kingdom;
      2013   Phase 3   EUCTR2012-001642-17-CZ   Argentina;Austria;Brazil;Canada;China;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United Kingdom;
      2013   -   EUCTR2012-001642-17-NL   Argentina;Austria;Brazil;Canada;China;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United Kingdom;
      2013   -   EUCTR2012-001642-17-DE   Argentina;Austria;Brazil;Canada;China;Czech Republic;Germany;Italy;Japan;Mexico;Netherlands;Russian Federation;Saudi Arabia;Spain;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-001642-17-AT   Argentina;Austria;Brazil;Canada;China;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;United Kingdom;
   GlaxoSmithKline, S.A.
      2013   -   EUCTR2012-001646-18-ES   Argentina;Austria;Brazil;Canada;China;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   -   EUCTR2012-001642-17-ES   Argentina;Austria;Brazil;Canada;China;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
Warfarin   
   Abe Kohtaro
      2021   Phase 3   JPRN-jRCT2071200098   Japan;
   Division of Cardiovascular Medicine, Department of Internal Medicine Kobe University Graduate School of Medicine
      2016   Phase 4   JPRN-UMIN000018520   Japan;
Warfarin Potassium   
   Kyushu University
      2021   Phase 3   NCT04730037   Japan;
[18F]Fluoro-2-deoxy-2-D-glucose   
   Brigham and Women's Hospital
      2013   Phase 2   NCT01953965   United States;